2 reports

  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.
  • Sep 05, 2017: H3 Biomedicine Announces First Patient Dosed with H3B-6545 in Phase 1 Study in Breast Cancer
  • Dec 06, 2017: H3 Biomedicine Presents Preclinical Data on Novel ERa Antagonist at San Antonio Breast Cancer Symposium

Summary H3 Biomedicine Inc (H3 Biomedicine), a subsidiary of Eisai Co Ltd is a biopharmaceutical company that offers therapies.The company concentrates on discovery and early development of novel, targeted anti-cancer compounds. Its products include small-molecule drugs that are developed by utilizing synthetic chemistry...

  • Cancer
  • Healthcare
  • Pharmaceutical
  • United States
  • H3 Biomedicine Inc.